Drugs / 3H-10000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07354711 | Jan 2026 → Jan 2028 expected | gastric cancer, lung cancer | 3H Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3H-10000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07354711 ↗ |
| Route | Other | “3H-10000 will be administered by infusion Q2W in 28-day cycles.” NCT07354711 ↗ |
| Target | FGFR2 | “3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate)” NCT07354711 ↗ |